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quality adjusted life years (QALY) gained. Resource utilization
focused on both cost of hospitalization and other community-
care costs such as pharmaceuticals and outpatient consultations.
Clinical trial data and other epidemiological literature were used
to elicit the event probabilities in the decision analytic model.
Utilities for each of the possible health states in the model were
derived from the Australian general population using the Assess-
ment Quality of Life (AQOL) utility instrument. RESULTS:
Against the weighted comparator risperidone long-acting injec-
tion was dominant. Analysis versus oral risperidone and oral
olanzapine also showed that risperidone long-acting injection
was dominant. The incremental cost-effectiveness ratio (ICER)
against typical depots produced a less favourable result due to
the low acquisition cost of these agents. Probabilistic sensitivity
analyses showed a 100% likelihood of an ICER of less than
$50,000 per QALY. CONCLUSIONS: Risperidone long-acting
injection represents a cost-effective intervention for patients who
are partially adherent to their medication. The model indicates
that introduction of risperidone long-acting injection in Australia
will result in signiﬁcant clinical and economic beneﬁts to the
community as partial adherence to medication is a major reason
for relapse of symptoms in patients with schizophrenia.
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OBJECTIVES: Parents of children with attention deﬁcit hyper-
activity disorder (ADHD) report problems with the need to take
medication three times per day. These problems include storage
and administration of a controlled substance at school and the
stigmatising impact on the child. The present study was designed
to estimate the utility gain associated with switching to a once
per day sustained release (OROS) treatment. METHODS: Clin-
ical data from OROS methylphenidate trials were used to deﬁne
health states associated with monotherapy and combination
therapy (addition of behavioural therapy). To determine the
utility gain with once daily therapy, the monotherapy and com-
bination therapy health states were further distinguished to
specify frequency of dosing. Forty-two interviews with parents
of children with ADHD were conducted where parents were
asked to rate the health states using a visual analogue scale (VAS)
and standard gamble (SG). RESULTS: The 1 per-day treatment
was given a higher valuation with the VAS ratings being 66.3
(±6.6) for the sustained release formulation and 51.0 (±7.2) for
the immediate release formulation. A difference was also
observed in the SG ratings with 0.90 (±0.05) and 0.86 (±0.07)
for the sustained release formulation and immediate release for-
mulation, respectively. These results were conﬁrmed by the val-
uations of the combination therapy health states. In general, the
ratings for monotherapy were given a higher valuation than com-
bination therapy. CONCLUSIONS: In this study, the health
states assumed equal effectiveness between a once-daily and a
three times daily preparation, in order to assess the utility dif-
ference resulting only from frequency of dosing. Participants
showed a preference for ADHD treatments with once daily
dosing.
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OBJECTIVES: Compare patient- and caregiver-reported out-
comes on 25 objective questions contained within the 51-item
Schizophrenia Outcomes Assessment Project (SOAP-51) quality
of life survey. METHODS: In total, 1500 community-residing
individuals with schizophrenia in ﬁve states (Massachusetts,
South Carolina, Wisconsin, Arizona, Washington) completed
SOAP-51 survey at baseline and weeks 4, 5, and 12. Previously,
factor analysis indicated SOAP-51 had eight factors (satisfaction,
self concept, work/role, mental health, interpersonal, medication
effects, activities of daily living, and physical function) with
Cronbach alphas ranging from 0.728–0.937 and test/retest intr-
aclass correlations >0.70 for all but one factor. An expert panel
identiﬁed 25 SOAP items that could be objectively measured.
This 25-item subset was given to each patient’s primary caregiver
concurrent with each patient’s SOAP-51 administration. Care-
givers were asked to answer each item in two ways: 1) What is
your objective response?, and 2) What do you think is the
patient’s response? Three correlation sets were performed for
week four responses: a) caregiver’s objective responses compared
to caregiver’s estimation of patient’s responses (Correlation A),
b) caregiver’s objective response compared to patient’s responses
(Correlation B); and caregiver’s estimation of patient’s responses
compared to patient’s responses (Correlation C). RESULTS:
Strongest correlations occurred in Correlation A [factor scores
for caregiver’s objective responses compared to caregiver’s esti-
mation of patient’s responses (0.534–0.862)]; lowest for Corre-
lation B [caregiver’s objective response compared to patient’s
responses (-0.292–0.367)]; and intermediate for Correlation C
[caregiver’s estimation of patient’s responses compared to
patient’s responses (-0.353–0.564)]. Physical function factor
correlations were the strongest in Correlation A (0.862), but the
lowest in Correlation B (-0.292) and C (-0.353). CONCLU-
SIONS: Caregiver objective assessments of individuals with
schizophrenia can vary markedly from patient-reported 
outcomes, but asking caregivers to view the world through the
eyes of the patient closes this gap. Asking caregivers to assume
a patient’s perspective may improve patient-caregiver 
communications.
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OBJECTIVES: Patient-reported outcomes such as health-related
quality of life (HRQL) are a frequent endpoint used in studies
of Major Depressive Disorder (MDD), but little is known if
results of these scales conducted during randomized clinical trials
(RCT’s) accurately reﬂect patients’ perceptions of the “real
world”. METHODS: An observational study and a randomized
double blind clinical trial with similar design, inclusion and
exclusion criteria and schedule of visits were used. These two
eight-week studies evaluated primary care MDD patients accord-
ing to the DSM-IV. Patients were asked to ﬁll in the EuroQoL
and the Quality of Life in Depression Scale (QLDS) at baseline
and eight weeks later, while physicians rated the severity of
